Summary
Shares of Eli Lilly (LLY) rose in premarket trading after Novo Nordisk disclosed that its experimental obesity therapy, CagriSema, failed to demonstrate non-inferiority to Eli Lilly's Tirzepatide on the trial's primary endpoint. The announcement prompted a marked move in both companies' U.S.-listed shares.
Market moves
Premarket activity showed Eli Lilly shares up 2.8%, trading at $1,037, while U.S.-listed Novo Nordisk stock fell 14.8% to $40.41. The market reaction followed Novo Nordisk’s release of top-line clinical results comparing CagriSema with Tirzepatide over an 84-week period.
Trial outcomes and next steps
In the head-to-head study, Novo Nordisk reported that CagriSema produced a 23% reduction in body weight over 84 weeks, versus a 25.5% reduction for Tirzepatide in the same timeframe. Novo Nordisk concluded the experimental drug did not meet the trial's non-inferiority standard. The company said it plans to initiate a higher-dose study of CagriSema in the second half of 2026 and still expects a U.S. Food and Drug Administration decision by late 2026.
Analyst perspective
J.P. Morgan commented that while CagriSema could add competitive choice for patients, it may be challenging for Novo Nordisk to capture market share from Eli Lilly. The bank highlighted that Eli Lilly’s Zepbound remains well established following the trial results and indicated expectations that Lilly may continue gaining share for Zepbound beyond 2026.
Implications
The immediate market response reflected investor preference toward Eli Lilly after the trial outcome. Novo Nordisk’s decision to pursue a higher-dose study signals an effort to address the gap identified in the head-to-head comparison. Both moves will be watched by market participants and stakeholders in the pharmaceutical and healthcare sectors as the companies advance clinical and regulatory timelines.
Concluding note
The developments leave Lilly advantaged in the near term on this particular comparative front, while Novo Nordisk is continuing clinical work aimed at improving performance of its candidate ahead of regulatory review.